Biokraft International AB reaffirmed earnings guidance for 2023. As previously communicated, 2023 will show weak underlying profitability given that company have a large share of fixed delivery contracts with fixed low prices that do not allow compensation for sharply increased costs.
1st Jan change | Capi. | |
---|---|---|
-24.48% | 540M | |
+50.00% | 177M | |
-10.17% | 103M |